S2 Episode 6: Clinical Trials and Novel Therapeutics in Psoriatic Arthritis S2 Episode 6: Clinical Trials and Novel Therapeutics in Psoriatic Arthritis
Join Drs Cohen and Gibofsky as they step through a case of refractory psoriatic arthritis, discuss novel therapeutics, review latest clinical trials, and talk about the future in psoriatic arthritis.Medscape (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - November 16, 2022 Category: Pathology Tags: Rheumatology InDiscussion Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life
SPRING HOUSE, PENNSYLVANIA, November 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER-2 study that show early (week 8) clinical improvementsa of most measures (joint and skin disease, enthesitis and dactylitis) in adult patients with active psoriatic arthritis (PsA) treated with TREMFYA® (guselkumab) were associated with meaningful improvements in health-related quality of life (HRQoL) (measured by EQ-5D)b from year one (week 52) through year two (week 100).1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor th...
Source: Johnson and Johnson - November 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Ted Danson says his psoriatic arthritis is 'killing him' - 'It's my hip'
Award-winning actor Ted Danson, 74, is struggling because of his arthritis. (Source: Daily Express - Health)
Source: Daily Express - Health - November 4, 2022 Category: Consumer Health News Source Type: news
Psoriatic Arthritis Has Greater Impact on Women Than Men Psoriatic Arthritis Has Greater Impact on Women Than Men
Women with PsA were more likely to have worse disease burden, pain, fatigue, quality of life, and greater disability and work impairment compared with men.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 25, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
New TREMFYA ® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with moderately to severely active ulcerative colitis (UC) with inadequate responses to previous treatments. The data presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting show an overall clinical response rate of approximately 80 percent in patients who were randomized to TREMFYA® (guselkumab).Clinical responsea at weeks 12 or 24 of the study was ultimately achieved by 80.2 percent of patients who w...
Source: Johnson and Johnson - October 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Managing Bad Days With Psoriatic Arthritis
Psoriatic arthritis flares are part of living with the condition. Find out how one woman deals with psoriatic arthritis flare-ups. (Source: WebMD Health)
Source: WebMD Health - October 20, 2022 Category: Consumer Health News Source Type: news
My Daily Life With Psoriatic Arthritis
Living with psoriatic arthritis means listening to your body. Here's how one woman manages everyday life with psoriatic arthritis. (Source: WebMD Health)
Source: WebMD Health - October 20, 2022 Category: Consumer Health News Source Type: news
The Challenges of Psoriatic Arthritis
Getting a diagnosis for psoriatic arthritis isn't always easy. Learn more about the challenges of this complex condition. (Source: WebMD Health)
Source: WebMD Health - October 20, 2022 Category: Consumer Health News Source Type: news
Adjusting to My Psoriatic Arthritis Diagnosis
A new psoriatic arthritis diagnosis means learning to manage your symptoms and the changes in your daily life. Learn how one man handled his diagnosis. (Source: WebMD Health)
Source: WebMD Health - October 20, 2022 Category: Consumer Health News Source Type: news
How to Make the Most of Psoriatic Arthritis Treatment
Effective treatment for psoriatic arthritis means finding what fits your condition and your life. Learn how doctors work to find the right treatments. (Source: WebMD Health)
Source: WebMD Health - October 20, 2022 Category: Consumer Health News Source Type: news
Living Your Best Life With Psoriatic Arthritis
Tips for living with psoriatic arthritis: Find out what one woman with the condition wishes she'd known. (Source: WebMD Health)
Source: WebMD Health - October 20, 2022 Category: Consumer Health News Source Type: news
Psoriatic Arthritis: How Remission Is Giving Me Hope
Psoriatic arthritis remission is possible. Find out the story of how one young man got to remission and gained hope for the future. (Source: WebMD Health)
Source: WebMD Health - October 20, 2022 Category: Consumer Health News Source Type: news
Advancements in Treating Psoriatic Arthritis
Psoriatic arthritis treatments offer more options than ever before. Learn about research into targeted therapy and other new psoriatic arthritis drugs. (Source: WebMD Health)
Source: WebMD Health - October 20, 2022 Category: Consumer Health News Source Type: news
Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
